Cáncer Colorectal

Estado: Finalizado

A Phase III, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer.

Para inscribirte contáctate a: [email protected]

Principales Criterios de Inclusión:

Histological confirmed previously treated colorectal cancer with adenocarcinoma histology with metastatic or recurrent unresectable disease at study entry
Participants must have:

  • Progressed during or within approximately 3 months following the last administration of approved standard therapies (at least 1, but not more than 4 prior lines of therapies), which must include a fluoropyrimidine, oxaliplatin, irinotecan, an anti-VEGF therapy, and anti-EGFR therapy (if KRAS wild-type), if available in the respective country, or;
  • Been intolerant to prior systemic chemotherapy regimens if there is documented evidence of clinically significant intolerance despite adequate supportive measures
  • Must have sufficient tumor tissue & evaluable PD-L1 expression to meet the study requirements
  • Must have measurable disease per RECIST v1.1. Participants with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately
Ciudades con sitios abiertos a enrolamiento:
  • Centro de Oncología de Precisión
  • Hospital U. de Chile

Consulta la Base de Datos
del Buscador de Ensayos Clínicos CIF

Si deseas conocer los datos de los Ensayos Clínicos en desarrollo, accede a nuestra base de datos que tenemos disponible aquí, con información actualizada trimestralmente.

Encuentra tu
ensayo clínico

Elige tu área de interés, patología o región, y accede a tu ensayo clínico.

Buscar ensayos >